TPX2 is known to regulate AURKA and interacts with RHAMM [71], which is known to correlate with centrosome amplification and with poor prognosis in MM [72]; the AURKA inhibitor is a potential treatment for MM [73]. Here, TPX2 is linked to Miyoshi myopathy.